SEC Filing Summary
Filing identity: The supplied filing is Manhattan Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2011—not a filing under the name TG Therapeutics, Inc. Confirm the issuer before relying on this summary.
Business context and reporting period
Manhattan described itself as a development-stage biopharmaceutical company focused on developing and commercializing treatments for underserved populations. It reported no product revenue through September 30, 2011. Its principal disclosed candidates included AST-726 for vitamin B12 deficiency and AST-915 for essential tremor; the Hedrin North American project was held through a joint venture.
Financial results and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2011 and 2010 | $0 in 2011 and 2010 |
| Operating loss | $262,000 in 2011; $516,000 in 2010 | $1.151 million in 2011; $1.570 million in 2010 |
| Net income (loss) | $(552,000) in 2011; $41,000 in 2010 | $298,000 in 2011; $258,000 in 2010 |
| Operating cash flow | Not separately presented for the quarter | $(166,000) in 2011; $(1.428 million) in 2010 |
The nine-month 2011 net income was not representative of product economics: it included a $4.517 million gain from the Nordic settlement, of which $4.017 million was noncash, and a $1.226 million loss on early extinguishment of debt. The quarter’s net loss reflected higher interest expense and the debt-extinguishment loss, partly offset by a favorable change in derivative fair value.
- Liquidity: Cash and cash equivalents were $212,000 at September 30, 2011, down from $479,000 at December 31, 2010. Current assets were $313,000 and current liabilities $1.515 million, for a working-capital deficit of about $1.202 million.
- Debt and liabilities: Notes payable totaled $17.150 million, excluding separately reported interest payable; total liabilities were $18.359 million. The $1.725 million principal balance of secured 12% notes plus $676,072 of interest converted into the right to receive 4,802,199 common shares. The company reported a $539,000 derivative liability.
- Equity: Stockholders’ deficiency was $295,000 at period-end. The company had 7,398,316 common shares issued and outstanding on its balance sheet; the filing also describes conversion shares as issuable pending issuance.
- Margins: No revenue was reported, so revenue margins are not meaningful.
Material changes versus prior comparable periods
- Nine-month operating expenses fell to $1.151 million from $1.570 million. Research and development expense rose 77% to $541,000, principally reflecting development activity and Ariston milestone shares; general and administrative expense declined 52% to $610,000, reflecting cost reductions and lower share-based compensation.
- Quarterly operating expenses declined to $262,000 from $516,000, while the company moved from $41,000 of net income to a $552,000 net loss.
- Nine-month operating cash use improved to $166,000 from $1.428 million, but cash balances declined. The company received $500,000 under the Nordic settlement and collected a $244,479 grant receivable during the 2011 period.
- The June 2011 1-for-50 reverse stock split and September debt conversion substantially changed the share count and triggered anti-dilution adjustments to certain warrants.
Outlook, risks, contingencies, and unusual items
- Management expected continued losses through at least September 2012 and said available resources were sufficient only through the end of 2011. It stated that additional equity or debt financing, licensing income, or strategic partnerships would be needed to sustain operations into 2012 and fund later development.
- The company said it lacked resources to conduct the pivotal AST-726 trial and would need financing or a development partner. It had reached agreement with the FDA on a special protocol assessment for the proposed Phase 3 study.
- The filing gives differing revenue timing statements: one passage says product-candidate revenue is not expected before June 30, 2012, if at all; another says not before September 30, 2012, if at all.
- A $250,000 note matured in October 2011; management was negotiating an extension. The filing also describes an ICON note balloon payment due January 31, 2012.
- The company expressly stated that these funding conditions raised substantial doubt about its ability to continue as a going concern. The financial statements included no adjustments for the outcome of that uncertainty.
- In a Hedrin-related arbitration, the joint venture sought about $7 million from licensor Thornton & Ross; Thornton & Ross asserted counterclaims and sought about $20 million, including claims against Manhattan. Manhattan said it believed the claims against it were without merit. Its Hedrin joint-venture interest had fallen to 11% after a further Nordic contribution.
- Disclosure controls were reported ineffective as of September 30, 2011 because financial and accounting duties were performed by one person. The filing reported no material change in internal control during the quarter.
- The filing reports no legal proceedings in Part II, although its notes and discussion describe the arbitration claims above.
Important facts for investors to verify
- Confirm that this Manhattan Pharmaceuticals filing is the intended issuer filing; the request names TG Therapeutics, Inc.
- Check the status of the October 2011 $250,000 maturity, the ICON note, and any financing or partnership secured after the reporting date.
- Reconcile the filing’s different revenue outlook dates and the common-share counts, including shares described as issuable from the debt conversion.
- Review subsequent developments in the Hedrin arbitration and the potential financial exposure to Manhattan.
- Assess whether financing was obtained to fund AST-726’s pivotal trial and whether the going-concern uncertainty was resolved.